EUDA Health Holdings Ltd. — FY 2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Financial statements are prepared under U.S. GAAP. Unless noted otherwise, amounts are U.S. dollars.
Business context and reporting period
EUDA is a British Virgin Islands holding company whose businesses have operated primarily in Singapore. In September 2023, it decided to streamline its medical-services operations, treating them as discontinued operations because the change represented a strategic shift. Continuing operations at year-end were property management and security services for residential and commercial properties. Management says it is exploring healthcare investments and licenses, including possible virtual-clinic services.
Key financial metrics
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Continuing-operations revenue | $3.706 million | $3.764 million |
| Gross profit | $842,075 | $869,999 |
| Gross margin | 22.7% | 23.1% |
| Operating loss | $3.961 million | $12.219 million |
| Net loss from continuing operations | $8.435 million | $25.008 million |
| Discontinued-operations result | $1.601 million loss | $58,659 income |
| Consolidated net loss | $10.036 million | $24.949 million |
| Net cash used in operating activities, consolidated | $2.918 million | $1.527 million |
| Cash at year-end, continuing operations | $189,005 | $57,541 |
| Working-capital deficit | Approximately $7.9–$8.0 million | Not clearly stated in the cited text |
Continuing-operations revenue was entirely from property management services. Cost of revenue was $2.864 million in 2023. The gross-margin decline was attributed mainly to higher salary and benefit costs per employee that were not passed on to customers. The filing reports consolidated total assets of $1.311 million, total liabilities of $8.792 million, and shareholders’ deficit of $7.482 million at December 31, 2023.
The cash-flow statement reports $3.214 million used by continuing operations and $296,000 provided by discontinued operations, resulting in $2.918 million of consolidated operating cash outflow. Financing activities provided $2.352 million net cash, while the overall cash and restricted-cash balance decreased by $586,931.
Material changes versus prior comparable period
- Continuing revenue declined 1.5% year over year. The mix shifted toward properties with security services: managed properties without security service fell from 37 to 34, while those with security service rose from 12 to 15.
- Operating loss narrowed substantially, largely because 2022 included a $5.2 million earnout-share charge and $1.1 million of long-lived-asset impairment, neither of which recurred in 2023. General and administrative expense also declined, partly because 2022 included substantial credit-loss provisions and write-offs.
- Other expense fell to $4.474 million from $12.809 million. However, 2023 included a $2.636 million loss on settling prepaid forward contracts and a $646,000 loss on debt settlements. The 2022 result included a $12.912 million fair-value loss on prepaid forward liabilities.
- Medical discontinued-operations revenue fell to $993,000 from $6.076 million, and the unit recorded a $1.601 million loss versus $58,659 income in 2022. Management cited lower post-pandemic demand.
- Shares outstanding increased to 24,627,509 at year-end from 20,191,770, including shares issued through private placements and settlements or conversions of debt and prepaid forward contracts.
Outlook, risks, contingencies, and unusual items
- Going concern: The auditor’s report includes an explanatory paragraph stating that substantial doubt exists about EUDA’s ability to continue as a going concern. The company reports recurring operating losses and negative operating cash flows since 2020, low cash, and a significant working-capital deficit. Management plans to seek bank, private-lender, equity, or convertible financing, but says funding is not assured. The financial statements contain no adjustments for the outcome of this uncertainty.
- Debt and liquidity: Year-end current liabilities were $8.717 million. These included $2.413 million of third-party convertible notes and $759,442 of related-party short-term loans; other payables and accrued liabilities were $1.887 million, with an additional $696,495 due to related parties. Some 2023 debt was settled with shares. After year-end, a $500,000 Gilandi loan automatically converted into 500,000 shares. A separate $1 million convertible loan agreed in April 2024 carries 12% interest and may convert into shares; terms vary with conversion timing. These subsequent events do not change the year-end balances.
- Acquisition after year-end: EUDA acquired CK Health, a Malaysian holistic-wellness product seller, on May 8, 2024, for 10 million newly issued shares valued at approximately $15 million. A further one million shares may be issued if specified 2024–2025 net-income milestones are met. A significant EUDA shareholder also owns 40% of the target.
- Internal controls: Management concluded internal control over financial reporting was ineffective at December 31, 2023 and 2022, citing insufficient accounting/reporting expertise, inadequate assessment of third-party specialists, and deficiencies in account reconciliations and journal-entry approvals. Remediation is planned but not yet demonstrated as effective.
- Legal matters: The filing describes disputes involving former directors and a company-filed claim alleging obstruction of access to systems. The claim remains ongoing, and any contingent gain cannot be estimated. Management does not expect the director disputes to have a material adverse effect.
- Business and market risks: The filing highlights customer concentration, competition, dependence on partners and service providers, technology and cybersecurity risks, healthcare regulation, foreign-exchange exposure, and the need to raise additional capital. One customer represented 11.3% of 2023 revenue; three customers represented 46.4% of year-end accounts receivable.
- Guidance: The filing provides no clear numerical forecast for future revenue, profit, or cash flow. Management describes plans to rebuild healthcare offerings and pursue growth, but notes budgetary and financial constraints have delayed development initiatives.
- Filing-status flag: The cover-page response indicates “No” to whether all required Exchange Act reports were filed during the preceding 12 months and the company had been subject to those requirements for 90 days. Investors should verify the reporting history and any related compliance implications.
Most important facts an investor should verify
- Current cash, working capital, payment obligations, and the status, amounts, and terms of financing obtained after December 31, 2023.
- Whether the company can continue funding operations and what dilution or other terms new financing may impose.
- CK Health’s financial performance, acquisition valuation, integration progress, and the conditions for any additional earnout shares.
- Whether the discontinued medical operations’ remaining liabilities, including the $2.624 million reported at year-end, have changed or require further cash outflows.
- Progress in remediating material weaknesses and any changes to auditor or SEC reporting status.
- Customer retention and concentration, property-management contract renewals, and whether higher labor costs can be passed through to customers.
- Developments in the pending legal matters and any resulting costs or recoveries.